The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic ...

Novo Nordisk’s diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday.

The Food and Drug Administration on Tuesday approved Novo Nordisk 's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

"All chronic kidney disease is progressive. It's a year-on-year, relentless decline in renal function," Stephen Gough, Novo Nordisk's global chief medical officer, said in an interview, referring ...

The FDA's decision means Ozempic can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.